155 related articles for article (PubMed ID: 12435371)
21. Quality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20).
Fosså SD; de Wit R; Roberts JT; Wilkinson PM; de Mulder PH; Mead GM; Cook P; de Prijck L; Stenning S; Aaronson NK; Bottomley A; Collette L; ;
J Clin Oncol; 2003 Mar; 21(6):1107-18. PubMed ID: 12637478
[TBL] [Abstract][Full Text] [Related]
22. First-line chemotherapy of non-seminomatous germ cell tumors(NSGCTs).
Pliarchopoulou K; Pectasides D
Cancer Treat Rev; 2009 Nov; 35(7):563-9. PubMed ID: 19576697
[TBL] [Abstract][Full Text] [Related]
23. Chemotherapy for good-risk germ-cell tumors.
Ryan CJ; Bajorin DF
Semin Urol Oncol; 2002 Nov; 20(4):244-50. PubMed ID: 12489057
[TBL] [Abstract][Full Text] [Related]
24. Testicular function in patients with testicular cancer treated with bleomycin-etoposide-carboplatin (BEC(90)) combination chemotherapy.
Pectasides D; Pectasides M; Farmakis D; Nikolaou M; Koumpou M; Kostopoulou V; Mylonakis N
Eur Urol; 2004 Feb; 45(2):187-93. PubMed ID: 14734005
[TBL] [Abstract][Full Text] [Related]
25. Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion.
Chevreau C; Mazerolles C; Soulié M; Gaspard MH; Mourey L; Bujan L; Plante P; Rischmann P; Bachaud JM; Malavaud B
Eur Urol; 2004 Aug; 46(2):209-14; discussion 214-5. PubMed ID: 15245815
[TBL] [Abstract][Full Text] [Related]
26. [Treatment of advanced testicular cancer and toxicity of chemotherapy].
Kawakita M; Matsuda T; Terachi T; Yoshida O
Hinyokika Kiyo; 1999 Nov; 45(11):783-6. PubMed ID: 10637744
[TBL] [Abstract][Full Text] [Related]
27. The management of poor-prognosis, non-seminomatous germ-cell tumours.
Sirohi B; Huddart R
Clin Oncol (R Coll Radiol); 2005 Oct; 17(7):543-52. PubMed ID: 16238142
[TBL] [Abstract][Full Text] [Related]
28. Management of good risk germ-cell tumours.
Troost MM; Sternberg CN; de Wit R
BJU Int; 2009 Nov; 104(9 Pt B):1387-91. PubMed ID: 19840018
[TBL] [Abstract][Full Text] [Related]
29. Oncological outcomes of metastatic testicular cancers under centralized management through regional medical network.
Inai H; Kawai K; Kojima T; Joraku A; Shimazui T; Yamauchi A; Miyagawa T; Endo T; Fukuhara Y; Miyazaki J; Uchida K; Nishiyama H
Jpn J Clin Oncol; 2013 Dec; 43(12):1249-54. PubMed ID: 24101656
[TBL] [Abstract][Full Text] [Related]
30. Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer. the Indiana University experience.
Behnia M; Foster R; Einhorn LH; Donohue J; Nichols CR
Eur J Cancer; 2000 Mar; 36(4):472-5. PubMed ID: 10717522
[TBL] [Abstract][Full Text] [Related]
31. The impact of bleomycin on retroperitoneal histology at post-chemotherapy retroperitoneal lymph node dissection of good risk germ cell tumors.
Cary KC; Pedrosa JA; Kaimakliotis HZ; Masterson TA; Einhorn LH; Foster RS
J Urol; 2015 Feb; 193(2):507-12. PubMed ID: 25254937
[TBL] [Abstract][Full Text] [Related]
32. Dose intense chemotherapy in the management of poor prognosis and relapsed testicular cancer: experiences and controversies.
Ng K; Duncan S; Shamash J; Alifrangis C
Expert Rev Anticancer Ther; 2018 May; 18(5):431-436. PubMed ID: 29557197
[TBL] [Abstract][Full Text] [Related]
33. Optimal number of chemotherapy courses in advanced nonseminomatous testicular carcinoma.
Kennedy BJ; Torkelson J; Fraley EE
Am J Clin Oncol; 1995 Dec; 18(6):463-8. PubMed ID: 8526185
[TBL] [Abstract][Full Text] [Related]
34. [New treatments for germ cell tumors with poor prognosis].
Arance A; García del Muro X; Montes A; Germà Lluch JR
Arch Esp Urol; 2000; 53(6):517-21. PubMed ID: 11002520
[TBL] [Abstract][Full Text] [Related]
35. [Treatment of metastatic germ cell tumors with etoposide and cisplatin as first line chemotherapy].
Shintaku I; Numahata K; Suzuki K; Ohyama C; Sato M; Saito S; Hoshi S; Orikasa S
Nihon Hinyokika Gakkai Zasshi; 2002 May; 93(4):519-24. PubMed ID: 12056035
[TBL] [Abstract][Full Text] [Related]
36. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.
Culine S; Kramar A; Théodore C; Geoffrois L; Chevreau C; Biron P; Nguyen BB; Héron JF; Kerbrat P; Caty A; Delva R; Fargeot P; Fizazi K; Bouzy J; Droz JP;
J Clin Oncol; 2008 Jan; 26(3):421-7. PubMed ID: 18202419
[TBL] [Abstract][Full Text] [Related]
37. [Testicular germ cell tumors: prognosis].
Miladi M; Peyromaure M; Remi J; Beuzeboc P; Debre B; Zerbib M
Prog Urol; 2003 Feb; 13(1):92-7. PubMed ID: 12703360
[TBL] [Abstract][Full Text] [Related]
38. Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours.
Fosså SD; Stenning SP; Gerl A; Horwich A; Clark PI; Wilkinson PM; Jones WG; Williams MV; Oliver RT; Newlands ES; Mead GM; Cullen MH; Kaye SB; Rustin GJ; Cook PA
Br J Cancer; 1999 Jul; 80(9):1392-9. PubMed ID: 10424741
[TBL] [Abstract][Full Text] [Related]
39. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M
Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521
[TBL] [Abstract][Full Text] [Related]
40. [Management of non-seminomatous germ cell tumors of the testes].
Kawai K; Akaza H
Gan To Kagaku Ryoho; 2000 Apr; 27(4):522-9. PubMed ID: 10790993
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
